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Abstract
Objective: Oral cancers are slow developing tumors that affect thousands of individuals in the US
annually. Evidence has shown that these cancers can create microenvironments to enhance their
progression, survival and metastasis characteristics. Cancer cells will compete for extracellular
nutrients with normal tissue cells, which can cause irregularities in immune regulation of
progressive cancers. Recent evidence in other types of cancers have suggested that tumor cells may
actually upregulate the consumption of extracellular L-tryptophan and increase the export of
cytosolic kynurenine byproduct. These kynurenines have been linked to suppression of local
immune response of T-cells. The primary goal of this study was to evaluate oral cancer cell lines for
tryptophan dioxygenase (TDO) and Indolamine 2,3-dioxygenase (IDO) expression and elucidate
whether or not other flavonoids inhibit enzyme expression and cancer growth. Methods: Oral
cancer cell lines SCC25, SCC15, and CAL27 were screened for enzyme expression using mRNA
specific primers and RT-PCR. The three cell lines were then subjected to proanthocyanidin (PAC)
administration to determine potential growth and enzyme inhibition. Results: This study found that
IDO and TDO are expressed in the SCC25, SCC15, and CAL27 oral cancer cell lines and enzyme
expression is correlated with tumor growth. Additionally, it was observed that IDO and TDO
expression, along with tumor growth, can be inhibited by flavonoid administration. Conclusions:
With no real treatment advances in many years and survival rates remaining relatively unchanged,
these results provide further knowledge in the understanding of oral cancer mechanisms and
function that may lead to future treatment modalities. Our demonstration of enzyme down
regulation and growth inhibition induced by flavonoids may also contribute to further research in
future novel treatments.
© 2012 GESDAV

INTRODUCTION
Oral cancers develop very slow over many years or
decades and have recently been found to affect nearly
30,000 people annually in the US [1,2]. Oral health
researchers and oncologists generally concur that most
oral cancers are initiated due to the long-term use of
tobacco and alcohol [3,4], although the mechanisms of
oral carcinogenesis entail distinct and variable changes
in the molecular systems, architecture, and genetics of
each individual tumor [5,6]. Recent evidence suggests
that aggressive tumors, including those of the oral
cavity, create microenvironments with many common
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features that promote tumor progression, survival,
angiogenesis, and metastasis [7].
One common cellular feature of oral cancers is
accelerated growth and proliferation, which is
dependent upon the uptake and metabolism of various
micronutrients used in biosynthesis and energy
generation [8,9]. For example, research has
demonstrated that folic acid, which is crucial for DNA
synthesis and repair, as well as specific metabolic
processes, including DNA methylation via Sadenosylmethionine, is closely regulated in most
tissues but may be dysregulated during oral
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carcinogenesis [10-14]. More recent evidence now
suggests that L-Tryptophan, an amino acid essential for
growth and a variety of other cellular processes,
including protein synthesis and both NADH / NADPH
formation [15], may be preferentially imported and
metabolized in many human cancers [16], such as those
of the oral cavity [15,17].
Uptake of L-tryptophan into human cells may involve a
variety of L-amino acid transporter (LAT) proteins,
but mainly LAT1 counter-transport proteins that import
extracellular
L-tryptophan in exchange for the
cytosolic by-product kynurenine following tryptophan
catabolism within the cell by tryptophan 2,3dioxygenase (TDO) and indoleamine 2,3-dioxygenase
enzymes (IDO) [18,19,20].
This exchange system
functions not only to accelerate carcinogenesis by
increasing L-tryptophan uptake from the local
microenvironment, thus reducing availability to other
cells, but also by up-regulating the export and
extracellular concentration of kynurenines, which may
play a significant role in suppressing the local adaptive
immune response of T-cells [21-26].
OBJECTIVE
A few preliminary studies have observed the
tryptophan influx/kynurenine efflux cycle in one or
more oral cancer cell lines [15,17]. Several studies have
demonstrated increased anti-tumor immunosuppression
and tumor growth inhibition by down-regulation or
interference with IDO [27-29]. However, only one
study to date has successfully demonstrated IDO
inhibition, transcriptional down-regulation, and growth
inhibition in oral cancer cells (using the flavonoid
epigallocatechin-3-gallate), as well as the elucidation of
associated intracellular signaling pathways affected
[17]. Therefore, the purpose of this study was to
evaluate additional oral cancer cell lines, not previously
examined, for IDO and TDO expression and to explore
the inhibitory potential of other flavonoids on IDO and
TDO expression. Based upon previous evidence, the
working hypothesis was that cellular phenotypes that
exhibit accelerated growth and proliferation may be
correlated with expression of these enzymes.
Furthermore, flavonoids may not only inhibit oral
cancer growth but also IDO and TDO expression.
These findings may be useful as they explore the
potential effects of flavonoids as prevention and
secondary treatment options for patients with oral
cancer.
METHODS
Cell
lines
The human oral scquamous cell carcinoma (OSCC) cell
lines used in this study, CAL27 (CRL-2095), SCC15
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(CRL-1623), and SCC25 (CRL-1628) were obtained
from American Type Culture Collection (ATCC:
Manassas, VA). CAL27 cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4
mM L-glutamine, adjusted to contain 3.7 g/L sodium
bicarbonate and 4.5 g/L glucose from Hyclone (Logan,
UT). SCC15 and SCC25 cells were maintained in a 1:1
mixture of DMEM and Ham’s F12 medium with 2.5
mM L-glutamine, modified to contain 15 mM HEPES,
0.5 mM sodium pyruvate, and 1.2 g/L sodium
bicarbonate (ATCC), supplemented with 400 ng/ml
hydrocortisone from Sigma-Aldrich (St. Louis, MO).
The control oral cell line HGF-1 (CRL-2014) was
maintained in DMEM with 4 mM L-glutamine,
adjusted to contain 3.7 g/L sodium bicarbonate and 4.5
g/L glucose, from Hyclone (Logan, UT). Media for all
cell lines were supplemented with 10% fetal bovine
serum (FBS), and with 1% Penicillin (10,000
units/mL)-Streptomycin (10,000 μg/mL) solution
(HyClone). Cell cultures were maintained in 75 cm2
Becton, Dickinson (BD) Falcon tissue-culture treated
flasks (Bedford, MA) at 37°C and 5% CO2 in
humidified chambers.
RNA isolation, concentration, and yield
RNA was isolated from 1.5 x 107 cells of each of the
experimental cell lines, using ABgene Total RNA
Isolation Reagent (Epsom, Surrey, UK) in accordance
with the procedure recommended by the manufacturer.
RNA purity and concentration and purity were
calculated using UV spectroscopy. The absorbance of
diluted RNA samples (10 µL of RNA sample in 490 µL
nuclease-free water, pH 7.0) was measured at 260 and
280 nm. RNA purity was determined by calculating
the ratio of A260:A280, and comparing it to the
expected ratio which should be > 1.80. Concentration
of RNA samples was determined by the A260 reading
of 1 = 40 µg/mL RNA, based on an extinction
coefficient calculated for RNA in nuclease-free water.
Concentration was then calculated as 40 x A260
absorbance measure x dilution factor (50). Total yield
was determined by concentration x sample volume in
mL.
Example:
RNA standard
A260 = 0.75
Concentration = 40 x 0.75 x 50 = 1,500 µg/mL
Yield = 1,500 µg/mL x 1.0 mL = 1,500 µg or 1.5 mg
RNA
Reverse-transcription polymerase chain reaction (RTPCR)
To quantify the expression of specific mRNA, RTPCR was performed on total RNA using the ABgene
Reverse-iT One-Step RT-PCR Kit (ReadyMix Version)
and a Mastercycler gradient thermocycler (Eppendorf:
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Hamburg, Germany) using the following primers for
IDO [30], IDO2 [31], TDO [32], c-myc [33] , ornithine
decarboxylase ODC [34] , caspase-2 [35], caspase-8
[36], and GAPDH [37], synthesized by SeqWright
(Houston, TX):
IDO-forward
5′-TGTCCGTAAGGTCTTGCCAGG-3′;
IDO-reverse
5′-CGAAATGAGAACAAAACGTCC-3′;
IDO2-forward
5′-GACTACAAGAATGGCACACG-3’;
IDO2-reverse
5′ AATGTGCTCTTGTTGGGTTAC-3’;
TDO-forward
5’-GGG CATATG AAAAAACTCCCCGTAGAAGG3’;
TDO-reverse
5’-GGGGATCCTTAATCTGATTCATCACTGCTG
AAGTAGG-3’;
c-myc forward primer,
5’-TCCAGCTTGTACCTGCAGGATCTGA-3’;
c-myc reverse primer,
5’-CCTCCAGCAGAAGGTGATCCAGACT-3’;
ODC forward primer,
5’-AATCAACCCAGCGTTGGACAA-3’;
ODC reverse primer,
5’-ACATCACATAGTAGATCGTCG-3’;
caspase-2 forward primer,
5’-TGGCATATAGGTTGCAGTCTCGG-3’;
caspase-2 reverse primer,
5’-TGTTCTGTAGGCTTGGGCAGTTG-3’;
caspase-8 forward primer,
5’-GATATTGGGGAACAACTGGAC-3’;
caspase-8 reverse primer,
5’-CATGTCATCATCCAGTTTGCA-3’;
GAPDH forward primer,
5’-ATCTTCCAGGAGCGAGATCC-3’;
GAPDH reverse primer,
5’-ACCACTGACACGTTGGCAGT-3’;
One µg of template (total) RNA was used for each
reaction. The reverse transcription step ran for 30
minutes at 47°C, followed by denaturation for 2
minutes at 94°C. Thirty-five amplification cycles were
run, consisting of 20 second denaturation at 94°C, 30
seconds of annealing at 58°C, and 6.5 minutes of
extension at 72°C. Final extension was run for 5
minutes at 72°C. Reaction products were separated by
gel electrophoresis using Reliant 4% NuSieve® 3:1
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Plus Agarose gels (Lonza: Rockland, ME). Bands were
visualized by UV illumination of ethidium-bromidestained gels and captured using a Kodak Gel Logic 100
Imaging System and 1D Image Analysis Software
(Eastman Kodak: Rochester, NY). Quantitation of RTPCR band densitometry and relative mRNA expression
levels were performed using Adobe Photoshop (San
Jose, CA) imaging software, Image Analysis tools.
Proliferation (growth) assays
Proliferation assays were performed in the appropriate
complete media in Corning Costar 96-well assay plates
(Corning, NY) at a concentration of 1.2 x 104 cells per
well, and proliferation was measured over three days.
Cultured cells were fixed at three time points, after 24
hrs (day 1 or d1), after 48 hrs (day 2 or d2), and after
72 hrs (day 3 or d3) using 50 μL of 10% buffered
formalin, and were stained with crystal violet 1%
aqueous solution (Fisher Scientific: Fair Lawn, NJ).
The relative absorbance was measured at 630 nm using
a Bio-Tek ELx808 microplate reader (Winooski, VT).
Data were analyzed and graphed using Microsoft Excel
(Redmond, WA). Three separate, independent
replications of each experiment were performed.
Relative-fold increase (RFI)
Trypsinizing and plating cells may have proliferationstimulating effects within laboratory cell culture-based
assays, which have been observed between d0 and d1
in previously published work involving this specific
method of proliferation assay in these cell lines [3843]. To reduce the overall impact of these effects, the
relative change in proliferation, measured as the change
or relative-fold increase (RFI) in absorbance between
d3 and d1, was calculated to more accurately assess the
changes induced by these experimental treatments.
Viability
Prior to plating cells for proliferation assays, aliquots of
trypsinized cells were stained using Trypan Blue
(Sigma: St. Louis, MO), and live cells were enumerated
by counting the number of Trypan-blue negative cells
using a VWR Scientific Counting Chamber (Plainfield,
NJ) and a Zeiss Axiovert 40 inverted microscope
(Gottingen, Germany). At each time point (day 1-3),
several wells were processed using the Trypan stain,
and live (viable) cells were enumerated, and the overall
percentage calculated, using this procedure.
Materials
Proanthocyanidin (PAC) (Lot #3717HF7361), a dietary
supplement intended to provide a concentrated source
of commonly available fruit-derived flavonoids, was
obtained from GNC Preventive Nutrition® (Pittsburgh,
PA). This commercial source of PAC was extracted
from U.S. grown wine grapes, Vitus vinifera. Such
commercial sources of grape seed PAC extract are
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demonstrated to contain 95% PAC and contain
approximately 80-90% oligomeric PACs, including
dimers, trimers, tetramers, and a small amount of other
monomers [41,42,44]. The total concentrations of PAC
used were between 10 and 100 μg/mL, added to the
complete media prior to the start of each experimental
assay and cell plating.
The growth inhibitory
maximum (GIMAX) previously determined for these
cell lines was confirmed at 50 µg/mL [41,42]. Three
independent replications of each experiment for each
cell line (CAL27, SCC25, SCC15) were performed,
each consisting of eight wells per experimental
concentration.

RESULTS

TDO IDO

SCC25

SCC15

CAL27

GAPDH

CAL27
SCC25

B
Figure 1.
To determine if proliferation or growth rates, measured
by relative-fold increase (RFI) in growth after three
days (3d), may be associated with these observations,
an analysis was performed revealing IDO mRNA
expression strongly correlated with RFI in CAL27,
SCC25, and SCC15 cells, R=0.90, 0.91, and 0.76,
respectively (Fig 1B). More specifically, the cell lines
with the highest RFI (CAL27 and SCC25) were
observed to express higher levels of IDO than SCC15
cells.
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RNA was extracted from the OSCC cell lines CAL27,
SCC25, and SCC15 to analyze IDO and TDO mRNA
expression using RT-PCR (Figure 1). This analysis
revealed expression of IDO and TDO mRNA in all
three cell lines, although the levels in each of the cell
lines varied significantly relative to their GAPDH
levels (Fig 1A). In addition, CAL27 and SCC25 cells
expressed comparatively greater levels of IDO mRNA
than did SCC15 cells.

SCC15
CAL27
SCC25

TDO IDO
- 240 bp

Statistics
Comparisons of the effects of treatments were made
using two-tailed t tests with α ≤ 0.05. All samples were
analyzed using two-tailed t tests as departure from
normality can make more of a difference in a one-tailed
than in a two-tailed t test [45]. As long as the sample
size is even moderate (>20) for each group, quite
severe departures from normality make little practical
difference in the conclusions reached from these
analyses.

A

TDO IDO

5
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CAL27
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Figure 2.
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To determine if these cell lines down-regulate IDO
expression and are growth-inhibited by flavonoids, as
previously observed with OSCC cell lines and
epigallocatechin [17], a more diverse group of
flavonoids (PACs) were administered at the GIMAX of
50 µg/mL (Figure 2). These experiments demonstrated
that PACs were sufficient to significantly inhibit
proliferation in a dose-dependent manner up to the
growth inhibitory maximum (GIMAX) of 50 µg/mL (36 to 58%, p<0.05), confirming previous observations
in CAL27 and SCC25 cells [40-42], but also
demonstrating these effects in SCC15 cells (Fig 2A).
To determine if the growth inhibition induced by PAC
administration also influenced IDO, RT-PCR was
utilized to reveal a down-regulation in IDO mRNA in
all cell lines (Fig. 2B). This decrease also corresponded
with a down-regulation in the cell-cycle promoter cmyc, confirming previous observations [40,41].
To more accurately assess these effects and the possible
mechanisms responsible, other key cell-cycle, survival
and apoptosis-specific regulatory genes, including
ODC, caspase-2, caspase-8, as well as TDO were
assessed (Table 1). These analyses demonstrated that
PAC administration is associated with down-regulation
of both IDO and TDO mRNA between -0.3 and -0.95fold. These analyses also confirmed the previously
observed down-regulation of key growth-promoting
regulators c-myc and ODC, as well as the up-regulation
of apoptosis initiators and effectors, caspase-2 and
caspase-8 [40]. Furthermore, these observations
correlated with decreased cell viability (ranging from 0.42 and 0.82-fold) and growth (between 0.36 and 0.58).
Table 1. PAC induced effects on mRNA expression, growth
and viability in oral cancer cells.
CAL27

SCC25

SCC15

IDO

-0.85

-0.95

-0.30

TDO

-0.50

-0.55

-0.30

c-myc

-0.90

-0.65

-0.45

ODC

-0.45

-0.60

-0.35

Caspase-2

+0.70

+1.10

+0.65

Caspase-8

+0.80

+0.60

+0.55

RFI

-0.58

-0.56

-0.36

Viability

-0.71

-0.83

-0.42

These data provide evidence that administration of
PACs may, directly or indirectly, down-regulate
mRNA expression of both IDO and TDO in oral cancer
cell lines (Figure 3). In addition, these data confirm
previous observations suggesting that other key oral
cancer cell-cycle signaling molecules, such as ODC
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and c-myc may also be down-regulated by PAC
administration [40-42] – although these data may be the
first to demonstrate that this process may occur in
tandem. When combined with other previous reports
of flavonoid-induced signaling interactions involving
STAT [17] and FAK [46], a more comprehensive
system involving the upstream and downstream effects
of flavonoid-induced growth inhibition of oral cancer
growth emerges.
IFN

GF

ECM

PM: plasma membrane
Trp transporter
LAT

RTK

integrin
Src/FAK*

Kynurenine

IDO

TDO
STAT*

c-myc*
c-myc

Ras/Raf
MEK
ERK1/2

ODC*
NM: nuclear membrane

Figure 3.

DISCUSSION
The purpose of this study was to investigate whether
previously unscreened oral cancer cell lines, expressed
IDO and TDO; and additionally to explore whether this
expression is correlated with any specific cellular
phenotype. To test this hypothesis, a comprehensive
series of integrated in vitro assays were performed that
clearly demonstrate SCC25 and SCC15 cells expressed
both IDO and TDO mRNA, as well as confirming this
expression in CAL27 oral cancer cells. In addition, the
differential expression of IDO, exhibited strong and
positive correlations with cellular growth and
proliferation rates. These experiments demonstrated
that PACs were sufficient to significantly inhibit
proliferation in a dose-dependent manner up to the
growth inhibitory maximum. Finally, although these
data confirm the growth-inhibitory properties of PACs
on oral cancers [40-42,47,48], these data may be the
first to demonstrate the potential for PACs and other
fruit-derived flavonoids to inhibit IDO (and TDO)
expression, similar to the effects previously observed
with epigallocatechin-3-gallate [17], as well as an
analysis of corresponding changes to key intracellular
signaling molecules involved in cell cycle progression
and the initiation of apoptosis.
Although several previous studies have evaluated the
potential pro-growth and immune-evasion mechanisms
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of IDO and TDO expression in other cancers [18-20],
to date, only a few select studies have examined these
processes in oral cancers [15,17]. The current study,
therefore, provides novel data and further elucidation
towards the understanding of how oral cancers function
not only to increase survival and viability, but also to
simultaneously down-regulate and evade local
immunomodulatory responses [21,22,25,26]. In
addition, these data provide novel evidence that IDO
mRNA expression, but not TDO levels, may be
correlated with oral cancer growth rates – a finding that
may help to contextualize the understanding of the
active, but differential, regulation of these enzymes in
other oral cancer cell lines and tumors. In addition, this
study provides novel data to suggest that PACs, and
other flavonoids, may be sufficient to inhibit growth
and down-regulate IDO expression in these cells.
A limitation of this study, similar to other preclinical
studies, involves the use of oral cancer cell lines.
These cells may harbor karyotypic alternations or other
dissimilar genetic mutations that may potentially
influence the experimental outcomes of this study. For
example, CAL27 cells contain a nonsense mutation in
the SMAD4 gene, which may influence the
transforming growth factor (TGF) signaling pathway
and cell growth potential [49]. In addition, SCC25 cells
are known to harbor a deletion in the cell cycle
promoter cdk1, resulting in a deletion of a critical
transcriptional regulation sequence [50]. SCC15 cells
however, harbor a single nucleotide polymorphism
(SNP) that alters the expression of the tumor
suppressor, S100A2 [51]. However, although oral
cancers may harbor many genetic mutations and
deletions, many lines of evidence now suggest that
dysregulation and reduced expression of many tumor
suppressors in oral cancers may, in fact, be the result of
hypermethylation events rather than fixed genetic
differences [52-54].
CONCLUSIONS
Although many studies have found that oral
carcinogenesis may be strongly influenced by the
ability of tumor cells to alter the local
microenvironment, new evidence suggests that the
ability to alter micronutrient uptake (L-tryptophan),
while down-regulating adaptive immune responses to
tumor growth may be critical to tumor growth and
metastasis. This study may be the first to provide new
evidence that IDO and TDO expression are found in
SCC25 and SCC15 cells, as well as CAL27 cells, and
to demonstrate that PAC administration is not only
sufficient to inhibit oral cancer growth, but may also be
associated with IDO and TDO mRNA downregulation.
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